These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25691064)

  • 1. About-face on the metabolic side effects of rapamycin.
    Salmon AB
    Oncotarget; 2015 Feb; 6(5):2585-6. PubMed ID: 25691064
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged rapamycin treatment led to beneficial metabolic switch.
    Fang Y; Bartke A
    Aging (Albany NY); 2013 May; 5(5):328-9. PubMed ID: 23645164
    [No Abstract]   [Full Text] [Related]  

  • 3. Duration of rapamycin treatment has differential effects on metabolism in mice.
    Fang Y; Westbrook R; Hill C; Boparai RK; Arum O; Spong A; Wang F; Javors MA; Chen J; Sun LY; Bartke A
    Cell Metab; 2013 Mar; 17(3):456-62. PubMed ID: 23473038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting mammalian target of rapamycin to promote longevity.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2012 Jun; 15(3):334-7. PubMed ID: 22758368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR, glycotoxins and the parallel universe.
    Green AS
    Aging (Albany NY); 2018 Dec; 10(12):3654-3656. PubMed ID: 30540565
    [No Abstract]   [Full Text] [Related]  

  • 6. Common toxicities of mammalian target of rapamycin inhibitors.
    Soefje SA; Karnad A; Brenner AJ
    Target Oncol; 2011 Jun; 6(2):125-9. PubMed ID: 21499766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
    Sibaud V; Dalenc F; Mourey L; Chevreau C
    Acta Derm Venereol; 2011 Sep; 91(5):584-5. PubMed ID: 21667012
    [No Abstract]   [Full Text] [Related]  

  • 8. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A; Martinet W; De Meyer GRY
    Transplantation; 2018 Feb; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
    Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
    Bourgier C; Massard C; Moldovan C; Soria JC; Deutsch E
    Ann Oncol; 2011 Feb; 22(2):485-6. PubMed ID: 21278224
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse events associated with mTOR inhibitors.
    Pallet N; Legendre C
    Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes.
    Pereira MJ; Palming J; Rizell M; Aureliano M; Carvalho E; Svensson MK; Eriksson JW
    Mol Cell Endocrinol; 2012 May; 355(1):96-105. PubMed ID: 22333157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardamonin ameliorates insulin resistance induced by high insulin and high glucose through the mTOR and signal pathway.
    Niu P; Zhang Y; Shi D; Chen Y; Deng J
    Planta Med; 2013 Apr; 79(6):452-8. PubMed ID: 23512499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longer and healthier life with TOR down-regulation: genetics and drugs.
    Bjedov I; Partridge L
    Biochem Soc Trans; 2011 Apr; 39(2):460-5. PubMed ID: 21428920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Koschei the immortal and anti-aging drugs.
    Blagosklonny MV
    Cell Death Dis; 2014 Dec; 5(12):e1552. PubMed ID: 25476900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
    [No Abstract]   [Full Text] [Related]  

  • 18. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.
    Miller RA; Harrison DE; Astle CM; Fernandez E; Flurkey K; Han M; Javors MA; Li X; Nadon NL; Nelson JF; Pletcher S; Salmon AB; Sharp ZD; Van Roekel S; Winkleman L; Strong R
    Aging Cell; 2014 Jun; 13(3):468-77. PubMed ID: 24341993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B; Citterio F
    Transplantation; 2012 Sep; 94(6):547-61. PubMed ID: 22941182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.